How to Improve Your Lipid Panel: Evidence-Based Strategies That Work

By
Published Updated Last reviewed
Medical lab testing image for How to Improve Your Lipid Panel: Evidence-Based Strategies That Work

At a glance

  • Optimal LDL-C / below 100 mg/dL for most adults, below 70 mg/dL for high-risk patients
  • Optimal HDL-C / 40 mg/dL or higher for men, 50 mg/dL or higher for women
  • Optimal triglycerides / below 150 mg/dL fasting
  • Total cholesterol target / below 200 mg/dL
  • Statin therapy / reduces LDL-C by 30% to 50% depending on intensity
  • Dietary saturated fat reduction / lowers LDL-C by 8% to 10%
  • Aerobic exercise / raises HDL-C by 3 to 6 mg/dL on average
  • Weight loss of 5% to 10% body weight / lowers triglycerides 20% to 30%
  • USPSTF screening recommendation / every 5 years starting at age 20
  • Fasting vs. Non-fasting draw / fasting preferred for accurate triglyceride measurement

What a Standard Lipid Panel Actually Measures

A standard lipid panel is a blood test that quantifies four values: total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides. Together, these markers give clinicians a snapshot of your cardiovascular lipid burden and help guide treatment decisions.

The Four Core Markers

LDL-C is the primary target in nearly every major guideline because it drives atherosclerotic plaque formation. HDL-C performs reverse cholesterol transport, carrying lipids away from artery walls. Triglycerides reflect circulating fat from recent meals and hepatic production. Total cholesterol is a composite of LDL-C, HDL-C, and VLDL-C (estimated as triglycerides divided by 5 in most labs).

Why the Panel Matters

The 2018 ACC/AHA Cholesterol Clinical Practice Guideline identifies LDL-C as the cornerstone of atherosclerotic cardiovascular disease (ASCVD) risk assessment [1]. The Framingham Heart Study, which has followed participants since 1948, established the causal link between elevated LDL-C and coronary events [2]. The USPSTF recommends lipid screening for all adults aged 20 and older at least every five years, with more frequent testing for those with risk factors [3].

A single lipid panel can change the clinical trajectory. For example, a 40-year-old with an LDL-C of 190 mg/dL qualifies for high-intensity statin therapy regardless of other risk factors, per ACC/AHA guidelines [1].

Fasting vs. Non-Fasting Draws

Most labs request a 9- to 12-hour fast before the draw. Triglycerides rise 20% to 30% after eating, which can inflate the calculated LDL-C value when using the Friedewald equation. A 2016 study in the European Heart Journal (N=300,000) found that non-fasting panels remain clinically useful for total cholesterol and LDL-C but may misclassify triglyceride status [4].

Normal Lipid Panel Ranges and What They Mean

Knowing your target ranges is the first step toward improvement. The National Cholesterol Education Program (NCEP) ATP III classifications, updated and reinforced by the 2018 ACC/AHA guideline, define the boundaries most labs reference on your results page.

Adult Reference Ranges

| Marker | Desirable | Borderline | High Risk | |---|---|---|---| | Total cholesterol | <200 mg/dL | 200 to 239 mg/dL | ≥240 mg/dL | | LDL-C | <100 mg/dL | 130 to 159 mg/dL | ≥160 mg/dL | | HDL-C | ≥60 mg/dL (protective) | 40 to 59 mg/dL | <40 mg/dL | | Triglycerides | <150 mg/dL | 150 to 199 mg/dL | ≥200 mg/dL |

The ACC/AHA pooled cohort equations use these values alongside age, sex, race, blood pressure, diabetes status, and smoking history to calculate a 10-year ASCVD risk score [1]. A score above 7.5% tips the balance toward statin initiation for most patients.

Context-Dependent Targets

An LDL-C of 95 mg/dL is acceptable for a healthy 30-year-old. That same number may be too high for someone who has already had a heart attack or carries a diagnosis of familial hypercholesterolemia. The 2022 ACC Expert Consensus Decision Pathway recommends an LDL-C below 55 mg/dL for very-high-risk patients with recurrent events [5].

Dietary Strategies to Improve Your Lipid Panel

Diet is the first intervention every guideline recommends. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly calls for "a diet emphasizing intake of vegetables, fruits, legumes, nuts, whole grains, and fish" as the foundation of lipid management [6].

Reduce Saturated Fat Intake

Replacing saturated fat with unsaturated fat lowers LDL-C by 8% to 10%, according to a 2020 Cochrane systematic review of 15 randomized controlled trials (N=59,000) [7]. The mechanism is straightforward: saturated fatty acids suppress hepatic LDL receptor expression, slowing clearance of LDL particles from the bloodstream. The American Heart Association recommends limiting saturated fat to less than 6% of total calories for adults needing LDL-C reduction [8].

Practical swaps include replacing butter with olive oil, choosing skinless poultry over processed red meat, and using avocado in place of cheese. These are not symbolic gestures. A meta-analysis in the BMJ (2015) found that each 5% replacement of saturated fat calories with polyunsaturated fat calories reduced coronary heart disease events by 10% [9].

Increase Soluble Fiber

Soluble fiber binds bile acids in the gut, forcing the liver to pull more cholesterol from the blood to synthesize replacements. A 2016 meta-analysis in the American Journal of Clinical Nutrition showed that 5 to 10 grams of soluble fiber daily reduces LDL-C by 5% to 11% [10]. Oats, barley, psyllium husk, and legumes are the most studied sources. Two servings of oatmeal (about 3 grams of beta-glucan) per day is a reasonable starting point.

Add Plant Sterols and Stanols

Plant sterols and stanols block intestinal cholesterol absorption. A dose of 2 grams per day lowers LDL-C by 8% to 10% per the Cleveland Clinic lipid management guidelines [11]. They are available in fortified margarine, orange juice, and supplement capsules.

The Mediterranean and DASH Patterns

The PREDIMED trial (N=7,447) demonstrated a 30% relative reduction in major cardiovascular events with a Mediterranean diet supplemented with extra-virgin olive oil or nuts, compared to a low-fat control diet [12]. The DASH diet, originally designed for blood pressure, also lowers LDL-C by 7% to 9% in controlled feeding studies [13].

Exercise and Physical Activity

Aerobic exercise is the single most effective non-dietary lifestyle change for raising HDL-C and lowering triglycerides. It also modestly lowers LDL-C.

Aerobic Exercise Raises HDL-C

A 2007 meta-analysis in the Archives of Internal Medicine (N=1,404 across 25 RCTs) found that aerobic exercise at moderate intensity raised HDL-C by an average of 2.53 mg/dL [14]. Higher volumes produced greater gains. The Endocrine Society and AHA both recommend at least 150 minutes per week of moderate-intensity aerobic activity (brisk walking, cycling, swimming) for lipid improvement [6][8].

Resistance Training Complements Cardio

Resistance training alone has modest effects on lipid profiles. But combined with aerobic exercise, it improves insulin sensitivity and body composition in ways that amplify triglyceride reduction. A 2019 systematic review in Sports Medicine found that combined training lowered triglycerides by 11% to 15% more than either modality alone [15].

Dose-Response Relationship

More exercise produces better results, up to a point. The STRRIDE trial at Duke University randomized sedentary adults to varying exercise intensities and found that the equivalent of jogging 20 miles per week improved every lipid marker, while the equivalent of walking 12 miles per week prevented worsening but produced smaller gains [16]. The clinically meaningful threshold appears to be about 120 to 150 minutes per week of moderate activity.

Weight Management and Body Composition

Excess adiposity, particularly visceral fat, drives triglyceride overproduction and suppresses HDL-C. Weight loss reverses both.

The 5% to 10% Threshold

A 2016 analysis from the Look AHEAD trial (N=5,145) showed that participants who lost 5% to 10% of body weight reduced triglycerides by 20% to 30% and raised HDL-C by 5 mg/dL on average [17]. LDL-C dropped by about 5% to 8%. These changes occurred regardless of whether the weight was lost through diet alone, exercise alone, or a combination.

GLP-1 Receptor Agonists and Lipids

Semaglutide 2.4 mg, studied in the STEP-1 trial (N=1,961), produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo [18]. Participants also saw triglycerides fall by 18.8% and C-reactive protein drop by 37.2%. Tirzepatide, studied in SURMOUNT-1 (N=2,539), produced 20.9% weight loss at the highest dose and demonstrated similar lipid improvements [19]. While these medications are not prescribed solely for lipid improvement, the downstream benefits are real and well-documented.

Visceral Fat Specifically

Waist circumference correlates more tightly with triglycerides than BMI alone. The AHA identifies a waist circumference above 40 inches in men and above 35 inches in women as a marker of cardiometabolic risk [8]. Reducing visceral fat through caloric deficit and aerobic exercise improves the triglyceride-to-HDL ratio, one of the strongest predictors of insulin resistance and small dense LDL particle burden.

Pharmacotherapy: When Lifestyle Is Not Enough

Lifestyle changes are necessary but sometimes insufficient. Genetics determine roughly 70% to 80% of circulating cholesterol levels. The 2018 ACC/AHA guideline identifies four statin benefit groups where pharmacotherapy is recommended [1].

Statin Therapy Remains First-Line

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. High-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) lower LDL-C by 50% or more. Moderate-intensity statins (atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg) lower LDL-C by 30% to 49% [1].

The CTT Collaborators meta-analysis of 26 statin trials (N=170,000) found that each 39 mg/dL (1 mmol/L) reduction in LDL-C reduced major vascular events by 22% over five years [20]. This is among the most replicated findings in cardiovascular medicine.

Ezetimibe as Add-On Therapy

Ezetimibe blocks the NPC1L1 transporter in the intestinal wall, reducing cholesterol absorption by about 50% and lowering LDL-C by an additional 15% to 20% when added to a statin. The IMPROVE-IT trial (N=18,144) confirmed that the combination of simvastatin plus ezetimibe reduced cardiovascular events by 6.4% relative to simvastatin alone over seven years [21].

PCSK9 Inhibitors for Refractory Cases

Evolocumab and alirocumab are monoclonal antibodies that block PCSK9, a protein that degrades LDL receptors. They lower LDL-C by 50% to 60% on top of statin therapy. The FOURIER trial (N=27,564) showed evolocumab reduced major cardiovascular events by 15% over a median 2.2 years [22]. These drugs are typically reserved for patients with familial hypercholesterolemia or clinical ASCVD who cannot reach goal on maximally tolerated statin plus ezetimibe.

Fibrates and Omega-3s for Triglycerides

Fenofibrate lowers triglycerides by 30% to 50% and is commonly prescribed for levels above 500 mg/dL, where pancreatitis risk becomes significant. Icosapent ethyl (Vascepa), a purified EPA omega-3, was studied in the REDUCE-IT trial (N=8,179) and reduced cardiovascular events by 25% in statin-treated patients with triglycerides between 135 and 499 mg/dL [23]. The FDA approved it specifically for cardiovascular risk reduction in this population.

Bempedoic Acid

For patients who cannot tolerate statins due to myalgia, bempedoic acid inhibits ATP citrate lyase upstream of HMG-CoA reductase. The CLEAR Outcomes trial (N=13,970) showed a 13% reduction in major cardiovascular events in statin-intolerant patients [24]. It lowers LDL-C by about 18% to 25% as monotherapy.

Supplements and Complementary Approaches

Certain supplements have lipid-modifying evidence behind them. Others do not. Precision matters here.

Red Yeast Rice

Red yeast rice contains monacolin K, which is chemically identical to lovastatin. A 2015 Cochrane review found it lowers LDL-C by about 15% to 25% [25]. The problem: supplement formulations vary widely in monacolin K content, some contain citrinin (a nephrotoxin), and none are FDA-regulated as drugs. Patients who use it should be monitored as if they were on a statin, including liver function and CK levels.

Omega-3 Fatty Acids

Over-the-counter fish oil supplements lower triglycerides by 15% to 30% at doses of 2 to 4 grams of combined EPA and DHA per day, per AHA guidelines [8]. They do not lower LDL-C and may raise it slightly at high doses. Prescription icosapent ethyl (EPA only) is the formulation with proven cardiovascular outcome benefit [23].

Berberine

Berberine, a plant alkaloid, has shown LDL-C reductions of 20% to 25% in small trials, primarily in Chinese populations. A 2012 meta-analysis in Evidence-Based Complementary and Alternative Medicine pooled 11 RCTs (N=874) and found LDL-C reductions of 25 mg/dL on average [26]. Larger, more diverse trials are needed before routine recommendation.

Monitoring and Follow-Up

Repeat testing is the only way to know whether interventions are working. The ACC/AHA guideline recommends rechecking a fasting lipid panel 4 to 12 weeks after starting or adjusting therapy, then every 3 to 12 months once stable [1].

What Repeat Testing Tells You

A 4- to 6-week recheck after a statin initiation confirms drug response and adherence. If LDL-C drops by less than 30% on high-intensity therapy, the clinician should explore non-adherence, drug interactions, or secondary causes of hyperlipidemia (hypothyroidism, nephrotic syndrome, cholestatic liver disease).

Advanced Lipid Testing

Standard panels miss some risk. ApoB, lipoprotein(a), and LDL particle number (LDL-P) add information beyond LDL-C alone. The 2022 ACC Expert Consensus recommends measuring Lp(a) at least once in every adult, as elevated Lp(a) above 50 mg/dL is an independent, genetically determined risk factor that affects roughly 20% of the population [5]. Lp(a) does not respond to lifestyle changes or statin therapy; pelacarsen and other antisense therapies are currently in Phase 3 trials.

Tracking Non-HDL Cholesterol

Non-HDL cholesterol (total cholesterol minus HDL-C) captures all atherogenic particles, including VLDL and IDL remnants that LDL-C alone misses. The 2018 ACC/AHA guideline identifies non-HDL-C as a useful secondary target, aiming for a value 30 mg/dL above the LDL-C goal [1]. If your LDL-C goal is 70, your non-HDL-C goal is 100.

Alcohol, Smoking, and Sleep

These three modifiable factors are frequently overlooked in lipid discussions but carry measurable effects.

Moderate alcohol intake (one drink per day for women, up to two for men) raises HDL-C by 5% to 15%, but the AHA does not recommend starting alcohol for this purpose because of competing harms including liver disease and cancer risk [8]. Heavy drinking raises triglycerides sharply.

Smoking lowers HDL-C by 5 to 10 mg/dL on average and accelerates LDL oxidation, making particles more atherogenic. Cessation reverses the HDL-C suppression within 6 to 12 months [27].

Sleep deprivation (fewer than 6 hours per night) is associated with higher triglycerides and lower HDL-C. A 2019 study in the Journal of the American Heart Association found that adults sleeping fewer than 6 hours had a 22% higher odds of elevated triglycerides compared to those sleeping 7 to 8 hours [28]. Aim for 7 to 9 hours as the AHA Life's Essential 8 framework now recommends.

Frequently asked questions

›What is a normal standard lipid panel level?
A normal lipid panel shows total cholesterol below 200 mg/dL, LDL-C below 100 mg/dL, HDL-C at or above 40 mg/dL for men (50 for women), and triglycerides below 150 mg/dL fasting. These targets shift lower for patients with existing cardiovascular disease or diabetes.
›What does a high standard lipid panel mean?
A high lipid panel, particularly elevated LDL-C or triglycerides, signals increased atherosclerotic cardiovascular disease risk. LDL-C above 160 mg/dL or triglycerides above 200 mg/dL typically prompt lifestyle counseling and may warrant pharmacotherapy depending on your overall 10-year ASCVD risk score.
›What does a low standard lipid panel mean?
Low total cholesterol and LDL-C are generally favorable. Low HDL-C (below 40 mg/dL) is a concern because it impairs reverse cholesterol transport. Very low LDL-C below 40 mg/dL from medications has not shown safety issues in major trials like FOURIER and IMPROVE-IT, which followed patients for years.
›How quickly can I improve my lipid panel?
Dietary changes and exercise can produce measurable LDL-C reductions within 4 to 6 weeks. Statins reach near-maximal LDL-C lowering by 4 weeks. A follow-up lipid panel at 6 to 12 weeks after starting any intervention gives a reliable measure of response.
›Do I need to fast before a lipid panel?
A 9- to 12-hour fast is preferred for accurate triglyceride measurement. Non-fasting panels are acceptable for screening total cholesterol and LDL-C, but triglyceride values may read 20% to 30% higher after meals, potentially affecting calculated LDL-C via the Friedewald equation.
›Can exercise alone fix a bad lipid panel?
Exercise primarily raises HDL-C (by 2 to 5 mg/dL) and lowers triglycerides (by 10% to 20%). Its effect on LDL-C is modest, typically a 3% to 5% reduction. For significantly elevated LDL-C, exercise is an important complement to dietary changes and often medication, but rarely sufficient alone.
›What foods lower LDL cholesterol the most?
Oats and barley (soluble fiber), almonds and walnuts, soy protein, and plant sterol-fortified foods have the strongest evidence. Combining these in a portfolio diet pattern can lower LDL-C by 25% to 30%, approaching the effect of a low-dose statin, according to a 2011 JAMA study by Jenkins et al.
›Are statins the only medication for high cholesterol?
No. Ezetimibe reduces LDL-C by 15% to 20% and is often combined with statins. PCSK9 inhibitors like evolocumab lower LDL-C by 50% to 60% on top of statin therapy. Bempedoic acid is available for statin-intolerant patients. Inclisiran, a twice-yearly injection, is a newer option targeting hepatic PCSK9 production.
›How often should I get my lipid panel checked?
The ACC/AHA recommends every 4 to 6 years for average-risk adults starting at age 20. After starting or changing lipid-lowering therapy, recheck at 4 to 12 weeks. Once stable, testing every 3 to 12 months is typical depending on risk level.
›Does losing weight improve cholesterol?
Yes. A 5% to 10% body weight loss lowers triglycerides by 20% to 30%, raises HDL-C by about 5 mg/dL, and reduces LDL-C by 5% to 8%. The Look AHEAD trial confirmed these benefits in over 5,000 participants followed for multiple years.
›What is the difference between LDL-C and ApoB?
LDL-C measures the cholesterol mass carried inside LDL particles. ApoB counts the number of atherogenic particles directly, since each LDL, VLDL, and Lp(a) particle has exactly one ApoB molecule. ApoB may better predict cardiovascular risk when LDL-C and particle number are discordant, which occurs in about 20% of patients.
›Can supplements replace statins?
For most high-risk patients, no. Red yeast rice can lower LDL-C by 15% to 25% but has inconsistent potency and lacks FDA quality oversight. Berberine shows promise in small trials but is not guideline-endorsed. Supplements may be considered in low-risk patients who decline statins but should be monitored the same way.

References

  1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. https://pubmed.ncbi.nlm.nih.gov/30423393/
  2. Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease: six-year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33-50. https://pubmed.ncbi.nlm.nih.gov/13751193/
  3. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. JAMA. 2022;328(8):746-753. https://pubmed.ncbi.nlm.nih.gov/35997723/
  4. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile. Eur Heart J. 2016;37(25):1944-1958. https://pubmed.ncbi.nlm.nih.gov/27122601/
  5. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering. J Am Coll Cardiol. 2022;80(14):1366-1418. https://pubmed.ncbi.nlm.nih.gov/36031461/
  6. Arnett DK, Blumenthal RS, Baxter S, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646. https://pubmed.ncbi.nlm.nih.gov/30879355/
  7. Hooper L, Martin N, Jimoh OF, et al. Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev. 2020;5(5):CD011737. https://pubmed.ncbi.nlm.nih.gov/32428300/
  8. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association. Circulation. 2021;144(23):e472-e487. https://pubmed.ncbi.nlm.nih.gov/34724806/
  9. Jakobsen MU, O'Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis. Am J Clin Nutr. 2009;89(5):1425-1432. https://pubmed.ncbi.nlm.nih.gov/19211817/
  10. Jovanovski E, Yashpal S, Engelen A, et al. Effect of psyllium (Plantago ovata) fiber supplementation on LDL-cholesterol: a meta-analysis. Am J Clin Nutr. 2018;108(5):922-932. https://pubmed.ncbi.nlm.nih.gov/30239559/
  11. Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232(2):346-360. https://pubmed.ncbi.nlm.nih.gov/24468148/
  12. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. https://pubmed.ncbi.nlm.nih.gov/29897866/
  13. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10. https://pubmed.ncbi.nlm.nih.gov/11136953/
  14. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007;167(10):999-1008. https://pubmed.ncbi.nlm.nih.gov/17533202/
  15. Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med. 2014;44(2):211-221. https://pubmed.ncbi.nlm.nih.gov/24174305/
  16. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347(19):1483-1492. https://pubmed.ncbi.nlm.nih.gov/12421890/
  17. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154. https://pubmed.ncbi.nlm.nih.gov/23796131/
  18. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  19. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
  20. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. https://pubmed.ncbi.nlm.nih.gov/21067804/
  21. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-2397. https://pubmed.ncbi.nlm.nih.gov/26039521/
  22. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. https://pubmed.ncbi.nlm.nih.gov/28304224/
  23. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. https://pubmed.ncbi.nlm.nih.gov/30415628/
  24. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-1364. https://pubmed.ncbi.nlm.nih.gov/36876740/
  25. Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014;9(6):e98611. https://pubmed.ncbi.nlm.nih.gov/24897342/
  26. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654. https://pubmed.ncbi.nlm.nih.gov/23118793/
  27. Gepner AD, Piper ME, Johnson HM, et al. Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. Am Heart J. 2011;161(1):145-151. https://pubmed.ncbi.nlm.nih.gov/21167347/
  28. Petrov ME, Kim Y, Engeda J, et al. Relationship between sleep duration and cardiovascular risk factors. J Am Heart Assoc. 2019;8(17):e013459. https://pubmed.ncbi.nlm.nih.gov/31476921/